JP2025001671A5 - - Google Patents

Info

Publication number
JP2025001671A5
JP2025001671A5 JP2024155116A JP2024155116A JP2025001671A5 JP 2025001671 A5 JP2025001671 A5 JP 2025001671A5 JP 2024155116 A JP2024155116 A JP 2024155116A JP 2024155116 A JP2024155116 A JP 2024155116A JP 2025001671 A5 JP2025001671 A5 JP 2025001671A5
Authority
JP
Japan
Prior art keywords
mutations
peptide epitopes
mutation
peptide
mrna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024155116A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025001671A (ja
Filing date
Publication date
Priority claimed from JP2020572793A external-priority patent/JP2021529750A/ja
Application filed filed Critical
Publication of JP2025001671A publication Critical patent/JP2025001671A/ja
Publication of JP2025001671A5 publication Critical patent/JP2025001671A5/ja
Pending legal-status Critical Current

Links

JP2024155116A 2018-06-27 2024-09-09 個別化がんワクチンエピトープの選択 Pending JP2025001671A (ja)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US201862690441P 2018-06-27 2018-06-27
US62/690,441 2018-06-27
US201862757045P 2018-11-07 2018-11-07
US62/757,045 2018-11-07
US201962814200P 2019-03-05 2019-03-05
US62/814,200 2019-03-05
US201962855311P 2019-05-31 2019-05-31
US62/855,311 2019-05-31
JP2020572793A JP2021529750A (ja) 2018-06-27 2019-06-27 個別化がんワクチンエピトープの選択
PCT/US2019/039521 WO2020006242A1 (en) 2018-06-27 2019-06-27 Personalized cancer vaccine epitope selection

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2020572793A Division JP2021529750A (ja) 2018-06-27 2019-06-27 個別化がんワクチンエピトープの選択

Publications (2)

Publication Number Publication Date
JP2025001671A JP2025001671A (ja) 2025-01-08
JP2025001671A5 true JP2025001671A5 (https=) 2026-02-03

Family

ID=68986808

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020572793A Pending JP2021529750A (ja) 2018-06-27 2019-06-27 個別化がんワクチンエピトープの選択
JP2024155116A Pending JP2025001671A (ja) 2018-06-27 2024-09-09 個別化がんワクチンエピトープの選択

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2020572793A Pending JP2021529750A (ja) 2018-06-27 2019-06-27 個別化がんワクチンエピトープの選択

Country Status (10)

Country Link
US (1) US20210268086A1 (https=)
EP (1) EP3813848A4 (https=)
JP (2) JP2021529750A (https=)
KR (1) KR20210038886A (https=)
CN (1) CN113365639A (https=)
AU (1) AU2019293244B2 (https=)
CA (1) CA3104673A1 (https=)
MX (1) MX2021000193A (https=)
SG (1) SG11202012770RA (https=)
WO (1) WO2020006242A1 (https=)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
SG10201912038TA (en) 2014-04-23 2020-02-27 Modernatx Inc Nucleic acid vaccines
US11364292B2 (en) 2015-07-21 2022-06-21 Modernatx, Inc. CHIKV RNA vaccines
EP3324979B1 (en) 2015-07-21 2022-10-12 ModernaTX, Inc. Infectious disease vaccines
WO2017020026A1 (en) 2015-07-30 2017-02-02 Modernatx, Inc. Concatemeric peptide epitopes rnas
WO2017031232A1 (en) 2015-08-17 2017-02-23 Modernatx, Inc. Methods for preparing particles and related compositions
EP3364949A4 (en) 2015-10-22 2019-07-31 ModernaTX, Inc. CANCER VACCINES
EP3364981A4 (en) 2015-10-22 2019-08-07 ModernaTX, Inc. VACCINE AGAINST THE HUMAN CYTOMEGALOVIRUS
CA3002912A1 (en) 2015-10-22 2017-04-27 Modernatx, Inc. Nucleic acid vaccines for varicella zoster virus (vzv)
EP3364950A4 (en) 2015-10-22 2019-10-23 ModernaTX, Inc. VACCINES AGAINST TROPICAL DISEASES
TW201729835A (zh) 2015-10-22 2017-09-01 現代公司 呼吸道病毒疫苗
HRP20220652T1 (hr) 2015-12-10 2022-06-24 Modernatx, Inc. Pripravci i postupci unosa terapijskih sredstava
MA45052A (fr) 2016-05-18 2019-03-27 Modernatx Inc Polynucléotides codant pour jagged1 pour le traitement du syndrome d'alagille
CN116837052A (zh) 2016-09-14 2023-10-03 摩登纳特斯有限公司 高纯度rna组合物及其制备方法
MA46584A (fr) 2016-10-21 2019-08-28 Modernatx Inc Vaccin contre le cytomégalovirus humain
WO2018089851A2 (en) 2016-11-11 2018-05-17 Modernatx, Inc. Influenza vaccine
WO2018107088A2 (en) 2016-12-08 2018-06-14 Modernatx, Inc. Respiratory virus nucleic acid vaccines
WO2018111967A1 (en) 2016-12-13 2018-06-21 Modernatx, Inc. Rna affinity purification
US11229668B2 (en) * 2017-02-07 2022-01-25 Nantcell, Inc. Maximizing T-cell memory and compositions and methods therefor
US11752206B2 (en) 2017-03-15 2023-09-12 Modernatx, Inc. Herpes simplex virus vaccine
EP3595713A4 (en) 2017-03-15 2021-01-13 ModernaTX, Inc. RESPIRATORY SYNCYTIAL VIRUS Vaccine
WO2018170245A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Broad spectrum influenza virus vaccine
US11045540B2 (en) 2017-03-15 2021-06-29 Modernatx, Inc. Varicella zoster virus (VZV) vaccine
MA47790A (fr) 2017-03-17 2021-05-05 Modernatx Inc Vaccins à base d'arn contre des maladies zoonotiques
WO2018187590A1 (en) 2017-04-05 2018-10-11 Modernatx, Inc. Reduction or elimination of immune responses to non-intravenous, e.g., subcutaneously administered therapeutic proteins
US11786607B2 (en) 2017-06-15 2023-10-17 Modernatx, Inc. RNA formulations
ES2983060T3 (es) 2017-08-18 2024-10-21 Modernatx Inc Variantes de ARN polimerasa
WO2019036683A1 (en) 2017-08-18 2019-02-21 Modernatx, Inc. ANALYTICAL METHODS BY HPLC
WO2019036685A1 (en) 2017-08-18 2019-02-21 Modernatx, Inc. METHODS FOR HPLC ANALYSIS
WO2019046809A1 (en) 2017-08-31 2019-03-07 Modernatx, Inc. METHODS OF MANUFACTURING LIPID NANOPARTICLES
EP3681514A4 (en) 2017-09-14 2021-07-14 ModernaTX, Inc. RNA VACZINE AGAINST ZIKA VIRUS
WO2019148101A1 (en) 2018-01-29 2019-08-01 Modernatx, Inc. Rsv rna vaccines
MA53650A (fr) 2018-09-19 2021-07-28 Modernatx Inc Lipides peg et leurs utilisations
AU2019345067A1 (en) 2018-09-19 2021-04-08 Modernatx, Inc. High-purity peg lipids and uses thereof
CN113271926A (zh) 2018-09-20 2021-08-17 摩登纳特斯有限公司 脂质纳米颗粒的制备及其施用方法
US11351242B1 (en) 2019-02-12 2022-06-07 Modernatx, Inc. HMPV/hPIV3 mRNA vaccine composition
US11851694B1 (en) 2019-02-20 2023-12-26 Modernatx, Inc. High fidelity in vitro transcription
CN113795579A (zh) 2019-02-20 2021-12-14 摩登纳特斯有限公司 用于共转录加帽的rna聚合酶变体
CA3132975A1 (en) 2019-03-11 2020-09-17 Modernatx, Inc. Fed-batch in vitro transcription process
EP3938379A4 (en) 2019-03-15 2023-02-22 ModernaTX, Inc. Hiv rna vaccines
EP3901261A1 (en) 2020-04-22 2021-10-27 BioNTech RNA Pharmaceuticals GmbH Coronavirus vaccine
US11406703B2 (en) 2020-08-25 2022-08-09 Modernatx, Inc. Human cytomegalovirus vaccine
US11058751B1 (en) 2020-11-20 2021-07-13 Think Therapeutics, Inc. Compositions for optimized RAS peptide vaccines
US11421015B2 (en) 2020-12-07 2022-08-23 Think Therapeutics, Inc. Method of compact peptide vaccines using residue optimization
CN116710115A (zh) 2020-11-20 2023-09-05 思维疗法股份有限公司 用于优化的肽疫苗的组合物和方法
US12329811B2 (en) 2021-01-11 2025-06-17 Modernatx, Inc. Seasonal RNA influenza virus vaccines
US11464842B1 (en) 2021-04-28 2022-10-11 Think Therapeutics, Inc. Compositions and method for optimized peptide vaccines using residue optimization
US20220363937A1 (en) 2021-05-14 2022-11-17 Armstrong World Industries, Inc. Stabilization of antimicrobial coatings
JP2024533501A (ja) 2021-09-13 2024-09-12 オンコディーエヌエー 患者の腫瘍の個別化された新生抗原を生成する方法
EP4148146A1 (en) 2021-09-13 2023-03-15 OncoDNA Method to generate personalized neoantigens of a tumor of a patient
KR102753583B1 (ko) * 2021-11-11 2025-01-10 의료법인 명지의료재단 Kras 특이적 활성화 t 세포 유도용 항원 조성물
US12186387B2 (en) 2021-11-29 2025-01-07 BioNTech SE Coronavirus vaccine
US12529047B1 (en) 2021-12-21 2026-01-20 Modernatx, Inc. mRNA quantification methods
US20250144043A1 (en) * 2022-02-11 2025-05-08 Washington University Methods of assessing cancer
WO2024002985A1 (en) 2022-06-26 2024-01-04 BioNTech SE Coronavirus vaccine
WO2024014770A1 (ko) * 2022-07-14 2024-01-18 엠큐렉스 주식회사 mRNA 백신 및 치료제의 제조를 위한 변형된 RNA
JP2026502789A (ja) * 2022-10-31 2026-01-27 グリットストーン バイオ インコーポレイテッド 組み合わせパネルのセルフリーdnaモニタリング
EP4648793A1 (en) 2023-01-11 2025-11-19 ModernaTX, Inc. Personalized cancer vaccines
WO2025146078A1 (en) * 2024-01-04 2025-07-10 Everest Medicines (China) Co., Ltd. Cancer vaccines and uses thereof
US20250232833A1 (en) * 2024-01-13 2025-07-17 Noergaard Anders Kaare Cyclin D1 Based Cancer Vaccine
WO2025171182A1 (en) 2024-02-08 2025-08-14 Iovance Biotherapeutics, Inc. Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with cancer vaccine
CN120209073B (zh) * 2025-05-28 2025-09-23 北京立康生命科技有限公司 一种有利于抗原呈递的间隔肽

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20211595T1 (hr) * 2011-05-24 2022-01-21 BioNTech SE Individualizirana cjepiva protiv raka
WO2014071219A1 (en) * 2012-11-01 2014-05-08 Factor Bioscience Inc. Methods and products for expressing proteins in cells
CN118750591A (zh) * 2013-04-07 2024-10-11 博德研究所 用于个性化瘤形成疫苗的组合物和方法
SG10201912485PA (en) * 2015-05-13 2020-02-27 Agenus Inc Vaccines for treatment and prevention of cancer
WO2017020026A1 (en) * 2015-07-30 2017-02-02 Modernatx, Inc. Concatemeric peptide epitopes rnas
EP3364949A4 (en) * 2015-10-22 2019-07-31 ModernaTX, Inc. CANCER VACCINES
EP3576751A4 (en) * 2017-02-01 2021-08-04 ModernaTX, Inc. RNA ANTI-CANCER VACCINES

Similar Documents

Publication Publication Date Title
JP2025001671A5 (https=)
US11510973B2 (en) Alphavirus antigen vectors
JP2021529750A5 (https=)
JP2023164537A5 (https=)
AU2017363308B2 (en) Viral delivery of neoantigens
AU2018254526B2 (en) Neoantigen identification, manufacture, and use
JPWO2020006242A5 (https=)
Ruan et al. Brain-targeted CRISPR/Cas9 nanomedicine for effective glioblastoma therapy
Toes et al. Enhancement of tumor outgrowth through CTL tolerization after peptide vaccination is avoided by peptide presentation on dendritic cells
US20210196806A1 (en) Shared antigens
Wang et al. A Bimetallic Polymerization Network for Effective Increase in Labile Iron Pool and Robust Activation of cGAS/STING Induces Ferroptosis‐Based Tumor Immunotherapy
Sonaje et al. Self‐assembled pH‐sensitive nanoparticles: a platform for oral delivery of protein drugs
CN120435550A (zh) 一种由多个kras变异肽连接而成的抗原肽、编码该抗原肽的核酸及其用途
Wu et al. Development of effective tumor vaccine strategies based on immune response cascade reactions
JP2022502416A (ja) ネオエピトープを選択する方法
WO1998059244A1 (en) Identification of mhc binding peptides
US20230020089A1 (en) Shared neoantigen vaccines
EP3607968A1 (en) Virus-like particles to be used for causing immune response against hbv
CN109890408A (zh) 新表位疫苗组合物及其使用方法
US20230128001A1 (en) Hiv antigens and mhc complexes
JP2015166388A (ja) 免疫療法としての酵母ベースの治療用組成物
JPS6349077A (ja) ベクターウイルスおよびベクターウイルスを含む薬用組成物
Lu et al. Folate‐conjugated micelles and their folate‐receptor‐mediated endocytosis
CN115820696A (zh) 治疗性多价HPV mRNA疫苗及其制备方法
Yu et al. A nanoparticle-based anticaries vaccine enhances the persistent immune response to inhibit Streptococcus mutans and prevent caries